Bamber L - Search Results

1

Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.

van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW. van Bellen B, et al. Among authors: bamber l. Curr Med Res Opin. 2014 May;30(5):829-37. doi: 10.1185/03007995.2013.879439. Epub 2014 Jan 22. Curr Med Res Opin. 2014. PMID: 24432872 Clinical Trial.

2

Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.

Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH. Bookhart BK, et al. Among authors: bamber l. J Med Econ. 2014 Oct;17(10):691-5. doi: 10.3111/13696998.2014.946993. Epub 2014 Aug 4. J Med Econ. 2014. PMID: 25065536

3

Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.

Prins MH, Bamber L, Cano SJ, Wang MY, Erkens P, Bauersachs R, Lensing AW. Prins MH, et al. Among authors: bamber l. Thromb Res. 2015 Feb;135(2):281-8. doi: 10.1016/j.thromres.2014.11.008. Epub 2014 Nov 18. Thromb Res. 2015. PMID: 25483215 Clinical Trial.

4

Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.

Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, Cano SJ. Bamber L, et al. Thromb Haemost. 2013 Oct;110(4):732-41. doi: 10.1160/TH13-03-0243. Epub 2013 Jul 11. Thromb Haemost. 2013. PMID: 23846019 Clinical Trial.

5

The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients.

Cano SJ, Lamping DL, Bamber L, Smith S. Cano SJ, et al. Among authors: bamber l. Health Qual Life Outcomes. 2012 Sep 26;10:120. doi: 10.1186/1477-7525-10-120. Health Qual Life Outcomes. 2012. PMID: 23013426 Free PMC article. Clinical Trial.

6

Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.

Bamber L, Muston D, McLeod E, Guillermin A, Lowin J, Patel R. Bamber L, et al. Thromb J. 2015 Jun 11;13:20. doi: 10.1186/s12959-015-0051-3. eCollection 2015. Thromb J. 2015. PMID: 26074735 Free PMC article.

7

Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.

Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Cohen AT, et al. Among authors: bamber l. Thromb Haemost. 2017 Jan 5;117(1):57-65. doi: 10.1160/TH15-08-0686. Epub 2016 Oct 6. Thromb Haemost. 2017. PMID: 27709226

8

Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer.

Martinez C, Cohen AT, Bamber L, Rietbrock S. Martinez C, et al. Among authors: bamber l. Thromb Haemost. 2014 Aug;112(2):255-63. doi: 10.1160/TH13-09-0793. Epub 2014 Apr 3. Thromb Haemost. 2014. PMID: 24695909

9

[No title available]

[No authors listed] [No authors listed] PMID: 26532276

10

Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.

Filippatos G, Maggioni AP, Lam CSP, Pieske-Kraigher E, Butler J, Spertus J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Bamber L, Gheorghiade M, Pieske B. Filippatos G, et al. Among authors: bamber l. Eur J Heart Fail. 2017 Jun;19(6):782-791. doi: 10.1002/ejhf.800. Eur J Heart Fail. 2017. PMID: 28586537 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results